Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$821.05 USD

821.05
278,546

-8.38 (-1.01%)

Updated Nov 6, 2024 11:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Can Regeneron Pharma (REGN) Pull a Surprise in Q2 Earnings?

by Zacks Equity Research

Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release second-quarter 2017 results on Aug 3 and we expect focus on Eylea's performance.

    Tirthankar Chakraborty headshot

    5 Top Multibagger Biotech Stocks to Buy in the 2nd Half

    by Tirthankar Chakraborty

    Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.

      Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff

      by Zacks Equity Research

      Both stocks carry a Zacks Rank #2 (Buy).

        Apple's Tim Cook earns $145M in 2016, Tops S&P 500 CEOs

        by Zacks Equity Research

        Apple Inc.'s (AAPL) Chief Executive Officer (CEO) Tim Cook has been declared the highest-paid CEO in the U.S., per a Bloomberg's report of take-home pay for the top 25 S&P 500 CEOs.

          BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase

          by Zacks Equity Research

          BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).

            Roche (RHHBY) Launches Cobas Test for Bacterial Infections

            by Zacks Equity Research

            Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at the point of care.

              Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US

              by Zacks Equity Research

              Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.

                Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label

                by Zacks Equity Research

                Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion of its colorectal cancer drug, Vectibix.

                  Acorda Files NDA for Parkinson's Disease Candidate Inbrija

                  by Zacks Equity Research

                  Acorda Therapeutics, Inc. (ACOR) has submitted a new drug application to FDA for its late stage pipeline candidate Inbrija for treatment of patients suffering from Parkinson's disease.

                    Zacks.com featured highlights: Principal Financial Group, Regeneron Pharmaceuticals, Zebra Technologies, United Technologies and T. Rowe Price Group

                    by Zacks Equity Research

                    Zacks.com featured highlights: Principal Financial Group, Regeneron Pharmaceuticals, Zebra Technologies, United Technologies and T. Rowe Price Group

                      Sarepta Appoints Ex-Allergan Executive as CEO and President

                      by Zacks Equity Research

                      Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).

                        Robust 1H for Pharma/Biotech Sector, 3 Big Stocks to Buy

                        by Zacks Equity Research

                        The pharma and biotech industry has been blessed with good health in the first half of the year.

                          Arpita Dutt headshot

                          Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod

                          by Arpita Dutt

                          Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.

                            Neothetics' Fat Reduction Candidate Fails in Phase II Study

                            by Zacks Equity Research

                            Neothetics, Inc. (NEOT) announced disappointing top line results from a phase II proof-of-concept study, LIPO-202-CL-31, evaluating its lead candidate, LIPO-202, for reduction of submental subcutaneous fat.

                              Esperion's Combo Cholesterol Candidate Enters Phase III

                              by Zacks Equity Research

                              Esperion Therapeutics, Inc. (ESPR) received positive feedback from the FDA for initiation of a phase III bridging study, evaluating the combination of bempedoic acid (180 mg) and Zetia (10 mg) for an LDL-C lowering indication.

                                Teva/Xenon Nerve Pain Candidate Fails in Phase II Study

                                by Zacks Equity Research

                                Teva Pharmaceutical Industries Ltd. (TEVA) announced that a mid-stage study evaluating their pipeline candidate, topical TV-45070 for post-herpetic neuralgia (PNH) did not meet the primary endpoint.

                                  Strongbridge (SBBP) Shows Strength: Stock Moves Up 10.1%

                                  by Zacks Equity Research

                                  Strongbridge Biopharma plc (SBBP) moved big last session, as the company saw its shares rise over 10% on the day.

                                    Jeffrey Hymen headshot

                                    5 Biomedical Stocks That Are Expected To Surge

                                    by Jeffrey Hymen

                                    With the promise of regulatory reform on the horizon, investors have been excited about the biomedical space throughout the year. If you want to add some to your portfolio, check out these 5 biomedical stocks that are primed to skyrocket here.

                                      Agios/Celgene's Leukemia Candidate Positive in Phase I/II

                                      by Zacks Equity Research

                                      Agios Pharmaceuticals, Inc. (AGIO) has announced a positive efficacy and safety data from the ongoing phase I/II study on experimental candidate IDHIFA (enasidenib) at an oral session at the European Hematology Association (EHA).

                                        Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU

                                        by Zacks Equity Research

                                        Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.

                                          Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion

                                          by Zacks Equity Research

                                          Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion recommending marketing approval of a pediatric formulation of Mimpara for the treatment of secondary hyperparathyroidism

                                            Conatus's PSC Candidate Gets Orphan Designation in the U.S.

                                            by Zacks Equity Research

                                            Conatus Pharmaceuticals Inc. (CNAT) announced FDA's grant of Orphan Drug Designation (ODD) to its pipeline candidate IDN-7314 for treatment of primary sclerosing cholangitis.

                                              Novartis Cardiovascular Drug Positive, NSCLC Drug Approved

                                              by Zacks Equity Research

                                              Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.

                                                Kamada Withdraws Inhaled AAT Marketing Application in EU

                                                by Zacks Equity Research

                                                Kamada Ltd.'s (KMDA) decided to withdraw the marketing authorization application (MAA) for its inhaled formulation of Alpha-1 Antitrypsin (AAT) in the EU.

                                                  Here's Why Investors Are Glued to Vertex Pharma (VRTX) Stock

                                                  by Zacks Equity Research

                                                  Vertex Pharmaceuticals, Inc. (VRTX), has been attracting investor attention.